Share the Video:

Growing up: The next cycle of venture funding for psychedelic companies

Daniel Goldberg, Andrew Chomer, Lindsay Hoover, Sasha Cohen

Commercial investment comprises the majority of funding in the psychedelic sector, with nearly all investment going to drug discovery over the last two years. Meanwhile, many projects outside of the scope of commercial markets require financial support. By committing strategic funds and financial gifts to mission-driven businesses, drug policy reform, public health education, harm reduction, and diversity and inclusion initiatives, philanthropists and investors have an opportunity to shape the field. In this session, we will explore how constructive capital can build equity and social value in the burgeoning psychedelic economy.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

First responder and law enforcement perspectives on decriminalization and crisis response

First responders and law enforcement discuss challenges and opportunities on the crisis frontlines, exploring substance decriminalization effects, harm reduction, and public health-focused approaches for more compassionate crisis response models.

Lt Diane Goldstein (Ret), Chief Joseph Montoya (DPD), Sarko Gergarian, Kate Gonella

PS2023 Business Health Conditions Health Equity Policy and Advocacy Public Benefit Social Justice

Delivering patient-centered care in a profit-focused world

United States healthcare faces challenges in accessibility and alignment with patient needs. Leaders discuss patient-centered care and business success in a well-being economy.

Nathan Sackett, Kimberly Roddy, Le Ondra Clark Harvey, Deidra Somerville, Tyler Norris

PS2023 Harm Reduction Health Equity Policy and Advocacy Public Benefit Research Social Justice

The drug policy endgame: beyond public health

Seasoned leaders and activists delve into redefining drug policy, focusing on social justice, human rights, and harm reduction for a compassionate, equitable future. Join the discussion for transformative approaches.

Shaleen Title, Kassandra Frederique, Jason Ortiz

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research and Science Social Justice

Intellectual property: shadows and solutions

Traditional cultures use psychedelics, but companies are patenting therapies and compounds based on them. Discussion explores IP system improvements for innovation and public health protection.

Chris Byrnes, Laurel Kilgour, Leslie Booher

PS2023 Harm Reduction Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Giving and growth: the role of philanthropic funding in the psychedelic sector

Philanthropy and investors can support crucial psychedelic research and initiatives beyond commercial interests to shape the field and promote equity and social value in the psychedelic economy.

Sandy Samberg

PS2023 Business Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research and Science

The evolving financial landscape for psychedelic medicine

Funding for psychedelic medicine is evolving, with a rise in commercial capital alongside philanthropic support. Balancing financial interests with equitable access and learning from scaling challenges are key considerations.

Henry Elkus

PS2023 Harm Reduction Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Proactive harm reduction by preparing set, setting, and substance

Harm reduction superheroes delve into risk mitigation and benefit maximization, exploring mindset, setting, and substances for safer drug experiences and systemic change.

Mitchell Gomez, Phoenix aka Mohawk Greene

PS2023 Harm Reduction Policy and Advocacy Psychedelic Assisted Therapy Public Benefit Research and Science Substance Use Disorder

Panel discussion and Q&A with addiction researchers

Substance use disorder cases doubled during the pandemic, with over 100,000 drug overdose deaths in 2020. Research explores psychedelic-assisted therapy as a potential paradigm shift in addiction treatment efficacy.

Michael Bogenschutz, Matthew Johnson, Deborah Mash, Peter S. Hendricks

PS2023 Policy Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Visionary approaches: psychedelic policy in a global context

International drug policy, historically mirroring US prohibitionist approach, is evolving. Leaders propose regulatory solutions in context of broader drug reform for unified post-prohibition world.

Steve Rolles, Kasia Malinowska

Growing up: The next cycle of venture funding for psychedelic companies

Become a MAPS Member with a monthly donation

Related Videos